Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal CancerTakashi Kojima, Manish A. Shah, Kei Muro et al.|Journal of Clinical Oncology|2020Cited by 1.2k
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancerYelena Y. Janjigian, Hyun Cheol Chung, Jianming Xu et al.|Nature|2021Cited by 687
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialSun Young Rha, Xiaochun Zhang, Do‐Youn Oh et al.|The Lancet Oncology|2023Cited by 614
Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the EsophagusManish A. Shah, Ken Kato, Jared Lunceford et al.|JAMA Oncology|2018Cited by 518
Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trialYelena Y. Janjigian, Sun Young Rha, Akihito Kawazoe et al.|The Lancet|2023Cited by 461